These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28608285)

  • 1. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
    Vinué Á; Navarro J; Herrero-Cervera A; García-Cubas M; Andrés-Blasco I; Martínez-Hervás S; Real JT; Ascaso JF; González-Navarro H
    Diabetologia; 2017 Sep; 60(9):1801-1812. PubMed ID: 28608285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/Lymphotoxin β-Receptor pathway.
    Andrés-Blasco I; Vinué Á; Herrero-Cervera A; Martínez-Hervás S; Nuñez L; Piqueras L; Ascaso JF; Sanz MJ; Burks DJ; González-Navarro H
    Thromb Haemost; 2016 Aug; 116(2):379-93. PubMed ID: 27172975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
    Tashiro Y; Sato K; Watanabe T; Nohtomi K; Terasaki M; Nagashima M; Hirano T
    Peptides; 2014 Apr; 54():19-26. PubMed ID: 24418070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.
    Shiraishi D; Fujiwara Y; Komohara Y; Mizuta H; Takeya M
    Biochem Biophys Res Commun; 2012 Aug; 425(2):304-8. PubMed ID: 22842565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
    Gaspari T; Welungoda I; Widdop RE; Simpson RW; Dear AE
    Diab Vasc Dis Res; 2013 Jul; 10(4):353-60. PubMed ID: 23673376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.
    Recio C; Oguiza A; Lazaro I; Mallavia B; Egido J; Gomez-Guerrero C
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1953-60. PubMed ID: 25012131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice.
    Burgmaier M; Liberman A; Möllmann J; Kahles F; Reith S; Lebherz C; Marx N; Lehrke M
    Atherosclerosis; 2013 Dec; 231(2):427-35. PubMed ID: 24267262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.
    Lee YS; Park MS; Choung JS; Kim SS; Oh HH; Choi CS; Ha SY; Kang Y; Kim Y; Jun HS
    Diabetologia; 2012 Sep; 55(9):2456-68. PubMed ID: 22722451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages.
    Guo C; Huang T; Chen A; Chen X; Wang L; Shen F; Gu X
    Braz J Med Biol Res; 2016 Nov; 49(12):e5826. PubMed ID: 27878229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
    Bruen R; Curley S; Kajani S; Crean D; O'Reilly ME; Lucitt MB; Godson CG; McGillicuddy FC; Belton O
    Cardiovasc Diabetol; 2017 Nov; 16(1):143. PubMed ID: 29110715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice.
    Gonzalez-Navarro H; Vila-Caballer M; Pastor MF; Vinue A; White MF; Burks D; Andres V
    Front Biosci; 2007 Jan; 12():2291-8. PubMed ID: 17127239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
    Bruen R; Curley S; Kajani S; Lynch G; O'Reilly ME; Dillon ET; Brennan EP; Barry M; Sheehan S; McGillicuddy FC; Belton O
    J Pharmacol Exp Ther; 2019 Sep; 370(3):447-458. PubMed ID: 31270216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.
    Martínez-Hervás S; Vinué A; Núñez L; Andrés-Blasco I; Piqueras L; Real JT; Ascaso JF; Burks DJ; Sanz MJ; González-Navarro H
    Cardiovasc Res; 2014 Jul; 103(2):324-36. PubMed ID: 24788416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
    Hunter K; Hölscher C
    BMC Neurosci; 2012 Mar; 13():33. PubMed ID: 22443187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages.
    Brenner C; Franz WM; Kühlenthal S; Kuschnerus K; Remm F; Gross L; Theiss HD; Landmesser U; Kränkel N
    Int J Cardiol; 2015 Nov; 199():163-9. PubMed ID: 26197403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
    Li P; Tang Z; Wang L; Feng B
    Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling.
    González-Navarro H; Vinué A; Vila-Caballer M; Fortuño A; Beloqui O; Zalba G; Burks D; Díez J; Andrés V
    Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2187-94. PubMed ID: 18802016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.